FDA looks at Opdivo/Yervoy in first-line colorectal cancer

The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as a first-line therapy for patients with a particular form of colorectal cancer (CRC), providing an alternative to rival therapy Keytruda from Merck.